Mr. Martin joined Azenta Life Sciences in April 2026 as President of Multiomics. He brings over 30 years of leadership experience across the life sciences industry, with deep expertise in scaling global synthesis and genomics platforms and a strong track record of building and operating complex, high growth businesses.

Most recently, he served as Chief Executive Officer and a member of the Board of Directors of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he served in senior leadership roles at Danaher Corporation, including Senior Vice President, Genomic Medicines, and President of Integrated DNA Technologies (IDT) following their 2018 acquisition of IDT. Prior to the acquisition, Mr. Martin was Chief Operating Officer for IDT from 2007-2018 and spent more than a decade in positions of increasing responsibility before taking the global operations role.

Mr. Martin holds a bachelor’s degree in biochemistry from the University of Iowa.